PALO ALTO, Calif., Feb. 28, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc. (Origin) today announced the U.S. Food and Drug ...
The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a ...
Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
The drug, fosdenopterin, is a treatment for molybdenum cofactor deficiency (MoCD) type A. Babies born with this disease experience a rapid progression of neurological problems including seizures, ...
SAN FRANCISCO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Origin Biosciences today announced the US Food and Drug Administration (FDA) has accepted its New ...
PALO ALTO, Calif. and SOLANA BEACH, Calif. and AHMEDABAD, India, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that ...
The Ministry of Community Development (MOCD) announced the beginning of registration of People of Determination students for the next academic year 2024/2025 beginning from 15th April until 28th June ...
The Ministry of Community Development, MoCD, has launched four interactive channels under a new initiative named 'Taaluf' to provide family counselling for free to all UAE community members. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results